

2024 Information

Date of announcement	Date of announcement	Statement
2024/01/30	16:28:27	<p>Invited to brief recent operating results.</p> <p>1.Date of institutional investor conference:2024/01/31</p> <p>2.Time of institutional investor conference:15:00</p> <p>3.Location of institutional investor conference: Web conference</p> <p>4.Outline of institutional investor conference: Brief recent operating results</p> <p>5.Any other matters that need to be specified: NA</p>
2024/03/12	15:19:59	<p>Board of Directors approved the consolidated financial statements.</p> <p>1.Date of submission to the board of directors or approval by the board of directors: 2024/03/12</p> <p>2.Date of approval by the audit committee:2024/03/12</p> <p>3.Start and end dates of financial reports or annual self-assessed financial information of the reporting period (XXXX/XX/XX~XXXX/XX/XX): 2023/01/01~2023/12/31</p> <p>4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD): 1,204,159</p> <p>5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):350,323</p> <p>6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):160,300</p> <p>7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD): 364,190</p> <p>8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):294,721</p> <p>9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):294,721</p> <p>10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD): 2.70</p> <p>11.Total assets end of the period (thousand NTD):6,690,741</p> <p>12.Total liabilities end of the period (thousand NTD):1,590,788</p> <p>13.Equity attributable to owners of parent end of the period (thousand NTD):5,099,953</p> <p>14.Any other matters that need to be specified: NA</p>
2024/03/12	15:39:11	<p>The Board proposed earnings distribution.</p> <p>1.Date of the board of directors resolution :2024/03/12</p> <p>2.Year or quarter which dividends belong to:2023</p> <p>3.Period which dividends belong to:2023/01/01~2023/12/31</p> <p>4.Appropriations of earnings in cash dividends to shareholders (NT\$ per share):1.25</p> <p>5.Cash distributed from legal reserve and capital surplus to shareholders (NT\$ per</p>

		<p>share): 0</p> <p>6.Total amount of cash distributed to shareholders (NT\$):149,385,793</p> <p>7.Appropriations of earnings in stock dividends to shareholders (NT\$ per share):0</p> <p>8.Stock distributed from legal reserve and capital surplus to shareholders (NT\$ per share): 0</p> <p>9.Total amount of stock distributed to shareholders (shares):0</p> <p>10.Any other matters that need to be specified:0</p> <p>11.Per value of common stock: NTD10</p>
2024/03/12	15:39:37	<p>Convention of 2024 general shareholders' meeting.</p> <p>1.Date of the board of directors' resolution:2024/03/12</p> <p>2.Shareholders meeting date:2024/05/30</p> <p>3.Shareholders meeting location: NO.61, LN.309, HAIHU N. RD., LUZHU DIST. TAOYUAN CITY</p> <p>4.Shareholders' meeting will be held by means of (physical shareholders' meeting/ hybrid shareholders' meeting / virtual-only shareholders' meeting): physical shareholders' meeting</p> <p>5.Cause for convening the meeting (1) Reported matters: (1) Report on the compensation for employees and directors of 2023 (2) Report on the compensation for directors (3) Report on operating results of 2023 (4) Report by Audit Committee on auditing of 2023 financial statements (5) Report on donation to related parties (6) Report on transactions with related parties (7) Amendments to Rules of Procedure for Board of Directors Meeting</p> <p>6.Cause for convening the meeting (2) Acknowledged matters: (1) Recognition of 2023 operation report and financial statements (2) Distribution of retained earnings</p> <p>7.Cause for convening the meeting (3) Matters for Discussion: (1) Amendment to Article of Incorporation (2) Amendment to Rules of Procedure for Shareholders Meeting (3) Lifting ban on directors from running the same business as SCI</p> <p>8.Cause for convening the meeting (4) Election matters: NA</p> <p>9.Cause for convening the meeting (5) Other Proposals: NA</p> <p>10.Cause for convening the meeting (6) Extemporary Motions: NA</p> <p>11.Book closure starting date:2024/04/01</p> <p>12.Book closure ending date:2024/05/30</p> <p>13.Any other matters that need to be specified: NA</p>
2024/40/30	17:05:28	<p>The expected date for the approval of the First Quarter 2024 Financial Report by the board of directors.</p>

		<p>1.Date of a notice of the board of directors meeting is issued:2024/04/30</p> <p>2.Expected date of the board of directors meeting is convened:2024/05/09</p> <p>3.Expected year and quarter of the financial reports or the annual self-assessed financial information submitted to the board of directors or approved by the board of directors: First Quarter 2024 Financial Report</p> <p>4.Any other matters that need to be specified: None</p>
2024/05/09	15:40:44	<p>Board of Directors approved the consolidated financial statements.</p> <p>1.Date of submission to the board of directors or approval by the board of directors:2024/05/09</p> <p>2.Date of approval by the audit committee:2024/05/09</p> <p>3.Start and end dates of financial reports or annual self-assessed financial information of the reporting period (XXXX/XX/XX~XXXX/XX/XX): 2024/01/01~2024/03/31</p> <p>4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD): 309,879</p> <p>5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):91,873</p> <p>6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):45,030</p> <p>7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD): 55,843</p> <p>8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):44,509</p> <p>9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):44,509</p> <p>10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD): 0.37</p> <p>11.Total assets end of the period (thousand NTD):6,698,858</p> <p>12.Total liabilities end of the period (thousand NTD):1,556,960</p> <p>13.Equity attributable to owners of parent end of the period (thousand NTD):5,141,898</p> <p>14.Any other matters that need to be specified: NA</p>
2024/05/09	16:23:24	<p>Announcement for the change of juristic-person representative director.</p> <p>1.Date of occurrence of the change:2024/05/09</p> <p>2.Name of legal person: Mercuries & Associates Holding, Ltd.</p> <p>3.Name of the previous position holder: Aurora Chen</p> <p>4.Resume of the previous position holder: Director of Yushan Pharmaceuticals Inc.</p> <p>5.Name of the new position holder: Hsu, Chin-Hsin</p> <p>6.Resume of the new position holder:</p>

		<p>Attorney General of Mercuries & Associates Holding, Ltd.</p> <p>7.Reason for the change: Corporate Director Reassignment as Representative</p> <p>8.Original term (from _____ to _____):2022/06/21 to 2025/06/20</p> <p>9.Effective date of the new appointment:2024/05/10</p> <p>10.Any other matters that need to be specified: NA</p>
2024/05/30	15:46:44	<p>Notice of the resolutions of 2024 general shareholders' meeting.</p> <p>1.Date of the shareholders meeting:2024/05/30</p> <p>2.Important resolutions (1) Profit distribution/ deficit compensation: Approved the distribution of retained earnings. 61,403,843 shares represented by shareholders present in person or by proxy. (including 55,232,583 shares casted electronically) approval votes: 61,029,949 votes – 99.39% of the total represented at the time of voting. disapproval votes 281,855 votes – 0.45% of the total represented at the time of voting. Invalid votes: 0 votes - 0% of the total represented at the time of voting. abstention votes/no votes: 92,039 votes – 0.14% of the total represented at the time of voting.</p> <p>3.Important resolutions (2) Amendments to the corporate charter: Approved the amendments to Article of Incorporation. 61,469,843 shares represented by shareholders present in person or by proxy. (including 55,232,583 shares casted electronically) approval votes: 61,003,451 votes – 99.24% of the total represented at the time of voting. disapproval votes: 282,223 votes – 0.45% of the total represented at the time of voting. invalid votes: 0 votes - 0% of the total represented at the time of voting. abstention votes/no votes 184,169 votes - 0.29% of the total represented at the time of voting.</p> <p>4.Important resolutions (3) Business report and financial statements: Approved the operation report and financial statements of 2023. 61,403,843 shares represented by shareholders present in person or by proxy. (including 55,232,583 shares casted electronically) approval votes: 61,257,237 votes – 99.76% of the total represented at the time of voting. disapproval votes: 54,569 votes – 0.08% of the total represented at the time of voting. invalid votes: 0 votes - 0% of the total represented at the time of voting. abstention votes/no votes: 92,037 votes – 0.14% of the total represented at the time of voting.</p>

		<p>5.Important resolutions (4) Elections for board of directors and supervisors: NA</p> <p>6.Important resolutions (5) Any other proposals:</p> <p>(1) Approved the amendments to Rules of Procedure for Shareholders Meeting. 61,469,843 shares represented by shareholders present in person or by proxy. (including 55,232,583 shares casted electronically) approval votes: 61,002,818 votes – 99.24% of the total represented at the time of voting. disapproval votes 282,856 votes – 0.46% of the total represented at the time of voting. invalid votes: 0 votes - 0% of the total represented at the time of voting. abstention votes/no votes: 184,169 votes – 0.29% of the total represented at the time of voting.</p> <p>(2) Approved the Lifting ban on directors from running the same business as SCI. 61,469,843 shares represented by shareholders present in person or by proxy. (including 55,232,583 shares casted electronically) approval votes: 60,908,899 votes – 99.08% of the total represented at the time of voting. disapproval votes 389,606 votes – 0.63% of the total represented at the time of voting. invalid votes: 0 votes - 0% of the total represented at the time of voting. abstention votes/no votes: 171,338 votes – 0.27% of the total represented at the time of voting.</p> <p>7.Any other matters that need to be specified: NA</p>
2024/05/30	15:47:43	<p>Notice of Lifting of ban on new directors from running the same business as SCI.</p> <p>1.Date of the shareholders meeting resolution:2024/05/30</p> <p>2.Name and title of the director with permission to engage in competitive conduct: Director: Dr. Weichyun Wong, Director of Energenesis Biomedical CO., LTD.</p> <p>3.Items of competitive conduct in which the director is permitted to engage: Companies running the same or similar businesses with SCI.</p> <p>4.Period of permission to engage in the competitive conduct: During the term of the Director.</p> <p>5.Circumstances of the resolution (please describe the results of voting in accordance with Article 209 of the Company Act): Approved by more than two thirds of the voting rights exercised by the shareholders representing a majority of the outstanding shares.</p> <p>6.If the permitted competitive conduct belongs to the operator of a mainland China area enterprise, the name and title of the directors (if it is not the operator of a Mainland-area enterprise, please enter “N/A” below): NA</p>

		<p>7. Company name of the mainland China area enterprise and the director's position in the enterprise: NA</p> <p>8. Address of the mainland China area enterprise: NA</p> <p>9. Operations of the mainland China area enterprise: NA</p> <p>10. Impact on the company's finance and business: NA</p> <p>11. If the directors have invested in the mainland China area enterprise, the monetary amount of the investment and their shareholding ratio: NA</p> <p>12. Any other matters that need to be specified: NA</p>
--	--	--